Cargando…

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, D. G., Geoffroy, K., Marguerie, M., Khan, S. T., Martin, N. T., Kmiecik, J., Bobbala, D., Aitken, A. S., de Souza, C. T., Stephenson, K. B., Lichty, B. D., Auer, R. C., Stojdl, D. F., Bell, J. C., Bourgeois-Daigneault, M.-C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113265/
https://www.ncbi.nlm.nih.gov/pubmed/33976179
http://dx.doi.org/10.1038/s41467-021-22929-z
_version_ 1783690824293285888
author Roy, D. G.
Geoffroy, K.
Marguerie, M.
Khan, S. T.
Martin, N. T.
Kmiecik, J.
Bobbala, D.
Aitken, A. S.
de Souza, C. T.
Stephenson, K. B.
Lichty, B. D.
Auer, R. C.
Stojdl, D. F.
Bell, J. C.
Bourgeois-Daigneault, M.-C.
author_facet Roy, D. G.
Geoffroy, K.
Marguerie, M.
Khan, S. T.
Martin, N. T.
Kmiecik, J.
Bobbala, D.
Aitken, A. S.
de Souza, C. T.
Stephenson, K. B.
Lichty, B. D.
Auer, R. C.
Stojdl, D. F.
Bell, J. C.
Bourgeois-Daigneault, M.-C.
author_sort Roy, D. G.
collection PubMed
description By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor antigen to prime and boost anti-tumor immunity. By providing the additional advantage of directly killing cancer cells, oncolytic viruses (OVs) constitute ideal platforms for such treatment strategy. However, given that the targeted tumor antigen is encoded into the viral genomes, its production requires robust infection and therefore, the vaccination efficiency partially depends on the unpredictable and highly variable intrinsic sensitivity of each tumor to OV infection. In this study, we demonstrate that anti-cancer vaccination using OVs (Adenovirus (Ad), Maraba virus (MRB), Vesicular stomatitis virus (VSV) and Vaccinia virus (VV)) co-administered with antigenic peptides is as efficient as antigen-engineered OVs and does not depend on viral replication. Our strategy is particularly attractive for personalized anti-cancer vaccines targeting patient-specific mutations. We suggest that the use of OVs as adjuvant platforms for therapeutic anti-cancer vaccination warrants testing for cancer treatment.
format Online
Article
Text
id pubmed-8113265
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81132652021-05-14 Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination Roy, D. G. Geoffroy, K. Marguerie, M. Khan, S. T. Martin, N. T. Kmiecik, J. Bobbala, D. Aitken, A. S. de Souza, C. T. Stephenson, K. B. Lichty, B. D. Auer, R. C. Stojdl, D. F. Bell, J. C. Bourgeois-Daigneault, M.-C. Nat Commun Article By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor antigen to prime and boost anti-tumor immunity. By providing the additional advantage of directly killing cancer cells, oncolytic viruses (OVs) constitute ideal platforms for such treatment strategy. However, given that the targeted tumor antigen is encoded into the viral genomes, its production requires robust infection and therefore, the vaccination efficiency partially depends on the unpredictable and highly variable intrinsic sensitivity of each tumor to OV infection. In this study, we demonstrate that anti-cancer vaccination using OVs (Adenovirus (Ad), Maraba virus (MRB), Vesicular stomatitis virus (VSV) and Vaccinia virus (VV)) co-administered with antigenic peptides is as efficient as antigen-engineered OVs and does not depend on viral replication. Our strategy is particularly attractive for personalized anti-cancer vaccines targeting patient-specific mutations. We suggest that the use of OVs as adjuvant platforms for therapeutic anti-cancer vaccination warrants testing for cancer treatment. Nature Publishing Group UK 2021-05-11 /pmc/articles/PMC8113265/ /pubmed/33976179 http://dx.doi.org/10.1038/s41467-021-22929-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Roy, D. G.
Geoffroy, K.
Marguerie, M.
Khan, S. T.
Martin, N. T.
Kmiecik, J.
Bobbala, D.
Aitken, A. S.
de Souza, C. T.
Stephenson, K. B.
Lichty, B. D.
Auer, R. C.
Stojdl, D. F.
Bell, J. C.
Bourgeois-Daigneault, M.-C.
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_full Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_fullStr Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_full_unstemmed Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_short Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_sort adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113265/
https://www.ncbi.nlm.nih.gov/pubmed/33976179
http://dx.doi.org/10.1038/s41467-021-22929-z
work_keys_str_mv AT roydg adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT geoffroyk adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT margueriem adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT khanst adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT martinnt adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT kmiecikj adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT bobbalad adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT aitkenas adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT desouzact adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT stephensonkb adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT lichtybd adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT auerrc adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT stojdldf adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT belljc adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
AT bourgeoisdaigneaultmc adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination